Paclitaxel Plus Pembrolizumab vs. Paclitaxel Weekly in ER+ Luminal B Metastatic Breast Cancer
Status:
Not yet recruiting
Trial end date:
2025-04-01
Target enrollment:
Participant gender:
Summary
PELICAN is a randomised phase II trial that aims to evaluate the efficacy and safety of
paclitaxel plus pembrolizumab relative to paclitaxel alone, in patients with locally advanced
or metastatic ER-positive, HER2-negative, Luminal B breast cancer who have received no prior
chemotherapy for advanced or metastatic disease.
Patients will be randomised (2:1) to one of the two treatment arms:
- Pembrolizumab plus Paclitaxel
- Paclitaxel
Phase:
Phase 2
Details
Lead Sponsor:
Queen Mary University of London
Collaborators:
European Institute of Oncology Merck Sharp & Dohme Corp.